

Hypersensitivity Reactions to Biologicals: an EAACI position paper

Sevim Bavbek¹, Mauro Pagani², Emilio Alvarez-Cuesta³, Mariana Castells⁴, Adile Berna Dursun⁵, Sahar Hamadi⁶, Ricardo Madrigal-Burgaleta⁷, Soledad Sanchez-Sanchez⁸, and Alessandra Vultaggio⁹

¹Ankara University Faculty of Medicine

²ASST Mantova

³Hospital Ramón y Cajal

⁴Brigham and Women's Hospital

⁵Recep Tayyip Erdoğan University

⁶Division of Immunology and Allergy; Department of Medicine, Brigham and Women's Hospital

⁷St Bartholomew's Hospital, Barts Health NHS Trust

⁸ University Hospital Complex A Coruña (CHUAC),

⁹Azienda Ospedaliera Universitaria Careggi,

March 31, 2021

Abstract

Because of their selectivity, biologicals are crucial therapeutic agents in oncological, immunological, and inflammatory diseases and their use in clinical practice is broadening. Biologicals are among the most common drugs that can cause hypersensitivity reactions (HSRs), and this is primarily attributed to an explosion in new treatment options that has developed through personalized and precision medicine. Patients can develop HSRs to these agents during the first lifetime exposure or after repeated exposure. Despite its relatively high prevalence, the underlying mechanisms and optimal management of HSRs to biologicals remain incompletely explained. In this position paper, the authors provided evidence-based recommendations for the diagnosis and management of HSRs to biologicals. Additionally, the document defines unmet needs, which should be topics of future studies.

Hosted file

Complete manuscript with Tables and Figure Hypersensitivity Reactions to Biological Agents.pdf available at <https://authorea.com/users/405076/articles/516110-hypersensitivity-reactions-to-biologicals-an-eaaci-position-paper>